Quintrio
Home

PHARMACEUTICAL PREPARATIONS

BridgeBio Oncology Therapeutics, Inc. Common Stock

BBOT

BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.

Last trade $1.98
Day change $0.00 (0.00%)
Day range $1.92 – $2.08
Volume 179,804
Market cap $159M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$158.9M
Price / earnings
—
Price / book
0.54×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.44×

Profitability

Earnings per share
-$2.14
Return on assets
-49.54%
Return on equity
-58.47%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
4.08×
Quick ratio
4.08×
Cash ratio
1.5×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$151.03M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BBOT, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025
Revenue$0$0$0$0$0
Cost of revenue$0$0$0$0$0
Gross profit$0$0$0$0$0
Selling, general and administrative$7.9M$10.96M$6.38M$5.33M$14.13M
Research and development$29.59M$49.23M$39.8M$38.07M$35.05M
Total operating expenses$37.49M$60.19M$46.18M$43.41M$49.18M
Operating income-$37.49M-$60.19M-$46.18M-$43.41M-$49.18M
Interest expense$0$0$0$0$0
Income before taxes-$34.18M-$56.45M-$42.11M-$38.8M-$44.76M
Income taxes$0$0$0$0$0
Net income-$34.18M-$56.45M-$42.11M-$38.8M-$44.76M
Net income attributable to common shareholders-$34.18M-$56.45M-$42.11M-$38.8M-$44.76M
EBITDA-$37.3M-$60M-$45.99M-$42.99M-$49M
Basic earnings per share-$0.43-$705.20-$526.11-$0.48-$1.03
Diluted earnings per share-$0.43-$705.20-$526.11-$0.48-$1.03

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia

BridgeBio Oncology Therapeutics presented preclinical data on BBO-10203, a novel RAS:PI3Kα breaker that inhibits KRAS-mutant tumor growth without causing hyperglycemia, showing promising results in monotherapy and combination treatments with KRAS inhibitors.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.